Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in Eritrea

Abstract

The emergence and spread of <i>P. falciparum</i> lineages with both <i>Pfkelch13</i>-mediated partial resistance to artemisinin and deletions in <i>hrp2</i> and <i>hrp3</i> in Eritrea threaten to compromise regional malaria control and elimination campaigns. (Funded by the Bill and Melinda Gates Foundation and others; Australian New Zealand Clinical Trials Registry numbers, ACTRN12618001223224, ACTRN12618000353291, and ACTRN12619000859189.).